Last reviewed · How we verify

NCT05562531

Botulinum Toxin Administration on Masticatory Performance

Status unknown Last updated 7 December 2023
What this trial tests

trial in Temporomandibular Disorder in 30 participants. Status unknown.

Timeline
1 May 2022
Primary endpoint
1 October 2023
1 December 2023

Quick facts

Lead sponsorMarmara University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date1 May 2022
Primary completion1 October 2023
Estimated completion1 December 2023
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Marmara University

Who can join

Adults 18 to 50, any sex, with Temporomandibular Disorder or Bruxism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to evaluate the effect of botulinum toxin type A (BTX-A) injection on masticatory performance and nutritional status in temporomandibular disorder patients with bruxism caused by both intra-articular and extra-articular pathologies based on Research Diagnostic Criteria for temporomandibular disorders (TMD). The baseline and end masticatory performance, pain intensity, nutrition and anxiety statuses, and anthropometric measurements will be compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Temporomandibular Disorder

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05562531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing